Salvage therapy expands highly cytotoxic and metabolically fit resilient CD8 + T cells via ME1 up-regulation.
Joanina K GicobiZhiming MaoGrace DeFrancoJacob B HirdlerYing LiVianca V VianzonEmilia R DellaceccaMichelle A HsuWhitney BarhamYiyi YanAaron S MansfieldYi LinXiaosheng WuTaro HitosugiDawn OwenMichael P GramsJacob J OrmeFabrice LucienHu ZengSean S ParkHaidong DongPublished in: Science advances (2023)
Patients with advanced cancers who either do not experience initial response to or progress while on immune checkpoint inhibitors (ICIs) receive salvage radiotherapy to reduce tumor burden and tumor-related symptoms. Occasionally, some patients experience substantial global tumor regression with a rebound of cytotoxic CD8 + T cells. We have termed the rebound of cytotoxic CD8 + T cells in response to salvage therapy as T cell resilience and examined the underlying mechanisms of resilience. Resilient T cells are enriched for CX3CR1 + CD8 + T cells with low mitochondrial membrane potential, accumulate less reactive oxygen species (ROS), and express more malic enzyme 1 (ME1). ME1 overexpression enhanced the cytotoxicity and expansion of effector CD8 + T cells partially via the type I interferon pathway. ME1 also increased mitochondrial respiration while maintaining the redox state balance. ME1 increased the cytotoxicity of peripheral lymphocytes from patients with advanced cancers. Thus, preserved resilient T cells in patients rebound after salvage therapy and ME1 enhances their resiliency.
Keyphrases
- end stage renal disease
- reactive oxygen species
- newly diagnosed
- ejection fraction
- prognostic factors
- early stage
- climate change
- squamous cell carcinoma
- cell death
- cell proliferation
- dendritic cells
- patient reported outcomes
- stem cells
- mesenchymal stem cells
- transcription factor
- bone marrow
- risk assessment
- depressive symptoms
- social support
- risk factors
- patient reported
- regulatory t cells
- sleep quality
- immune response
- young adults